Vevye is a drug owned by Harrow Eye Llc. It is protected by 5 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2042. Details of Vevye's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12059449 | Ophthalmic composition for treatment of dry eye disease |
Apr, 2042
(17 years from now) | Active |
| US11413323 | Ophthalmic composition for treatment of dry eye disease |
Oct, 2039
(14 years from now) | Active |
| US11154513 | Semifluorinated compounds |
Nov, 2038
(14 years from now) | Active |
| US10813976 | Ophthalmic compositions comprising ciclosporin |
Sep, 2037
(12 years from now) | Active |
| US8614178 | Pharmaceutical composition for treatment of dry eye syndrome |
Dec, 2030
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vevye's patents.
Latest Legal Activities on Vevye's Patents
Given below is the list of recent legal activities going on the following patents of Vevye.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Apr, 2024 | US10813976 |
| Electronic Review Critical | 24 May, 2023 | US11413323 |
| Post Issue Communication - Certificate of Correction | 05 May, 2023 | US11413323 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Aug, 2022 | US11413323 |
| Recordation of Patent Grant Mailed Critical | 16 Aug, 2022 | US11413323 |
| Email Notification Critical | 28 Jul, 2022 | US11413323 |
| Issue Notification Mailed Critical | 27 Jul, 2022 | US11413323 |
| Dispatch to FDC | 22 Jun, 2022 | US11413323 |
| Application Is Considered Ready for Issue Critical | 22 Jun, 2022 | US11413323 |
| Issue Fee Payment Received Critical | 19 Jun, 2022 | US11413323 |
FDA has granted several exclusivities to Vevye. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vevye, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vevye.
Exclusivity Information
Vevye holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Vevye's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
US patents provide insights into the exclusivity only within the United States, but Vevye is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vevye's family patents as well as insights into ongoing legal events on those patents.
Vevye's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vevye:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Vevye(Cyclosporine) has 1 clinical trial that has been verified in 2024.
Generic Launch
Generic Release Date:
Vevye's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 01, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vevye Generic API suppliers:
Cyclosporine is the generic name for the brand Vevye. 14 different companies have already filed for the generic of Vevye, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vevye's generic
Alternative Brands for Vevye
Vevye which is used for managing symptoms of dry eye disease., has several other brand drugs in the same treatment category and using the same active ingredient (Cyclosporine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Bausch And Lomb Inc |
| |||||
| Oyster Point Pharma |
| |||||
| Sun Pharm |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Cyclosporine. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cyclosporine, Vevye's active ingredient. Check the complete list of approved generic manufacturers for Vevye
About Vevye
Vevye is a drug owned by Harrow Eye Llc. It is used for managing symptoms of dry eye disease. Vevye uses Cyclosporine as an active ingredient. Vevye was launched by Harrow Eye in 2023.
Approval Date:
Vevye was approved by FDA for market use on 30 May, 2023.
Active Ingredient:
Vevye uses Cyclosporine as the active ingredient. Check out other Drugs and Companies using Cyclosporine ingredient
Treatment:
Vevye is used for managing symptoms of dry eye disease.
Dosage:
Vevye is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | SOLUTION | Prescription | OPHTHALMIC |